Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Initial Clinical Trial of Valaciclovir for Fetal Treatment of Symptomatic Congenital Cytomegalovirus Infection
jRCTs031260254Recruiting
- Sponsor
- National Center for Child Health and Development
- Start
- Jul 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of valaciclovir in congenital cytomegalovirus infection (cCMV), sponsored by National Center for Child Health and Development. Primary endpoints: Maternal Grade ≥3 adverse events and Fetal and neonatal Grade ≥3 adverse events. Started Jul 2026; status: recruiting.
02
Drugs
valaciclovir
03
Conditions
congenital cytomegalovirus infection (cCMV)
Beyond the preview
Go deeper on jRCTs031260254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260254.